Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XBiotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
XBiotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XBiotech Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
XBiotech Enters into Agreement with Cedars-Sinai Medical Center 11
Xbiotech Enters into Research Agreement with Case Western Reserve University School of Medicine 12
Xbiotech Enters into Agreement with NCIC Clinical Trials 13
Xbiotech Enters into Research Agreement with South Texas Blood & Tissue Center 14
Licensing Agreements 15
XBiotech Enters into Licensing Agreement with CT Atlantic 15
Megapharm Enters into Licensing Agreement with XBiotech for Xilonix 16
Xbiotech Enters Into Licensing Agreement With Lonza Sales 17
XBiotech Enters Into Licensing Agreement With Strox Biopharma 18
Equity Offering 19
Xbiotech Raises USD31.8 Million in Public Offering of Shares 19
XBiotech Raises USD1 Million in Public Offering of Shares 20
XBiotech Raises USD1.8 Million in Public Offering of Shares 21
Xbiotech Raises USD76 Million in IPO 22
XBiotech Inc – Key Competitors 23
XBiotech Inc – Key Employees 24
XBiotech Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Corporate Communications 26
Sep 12, 2018: XBiotech appoints Dr. Peter Libby to its Scientific Advisory Board 26
Apr 10, 2017: XBiotech Announces Additions To Its Scientific Advisory Board 27
Product News 29
11/14/2017: XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions 29
11/03/2017: XBiotech’s MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions 30
10/03/2017: XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board 31
09/20/2018: XBiotech announces addition of top dermatologist and researcher Dr. Alice Gottlieb to its team 32
09/15/2017: Refusal of the marketing authorisation for Human IgG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech 33
09/13/2018: XBiotech Announces Completion and Positive Interim Findings for Initial Cohort in Bermekimab Pilot Study in Atopic Dermatitis 34
08/27/2018: Xbiotech announces publication of breakthrough findings for potential role of interleukin-1 alpha in risk for heart attacks 35
06/08/2017: EMA Adopts a Negative Opinion for Human IgG1 mAb Specific for Human Interleukin-1 Alpha XBiotech 36
Product Approvals 37
Apr 20, 2017: XBiotech Announces Outcome of EMA’s Oral Explanation Meeting 37
Clinical Trials 38
Sep 24, 2018: XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa 38
Jul 10, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa 39
May 22, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis 40
Apr 16, 2018: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology 41
Jan 26, 2018: XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 42
Jan 19, 2018: XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 43
Dec 04, 2017: XBiotech Announces Publication of Phase II Data From Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology 44
Oct 18, 2017: XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer 45
Sep 07, 2017: XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 46
Jun 09, 2017: XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis 47
Jun 01, 2017: XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting 48
May 30, 2017: Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer 49
Feb 22, 2017: XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application 50
Feb 21, 2017: Xbiotech Reports Affirmative Interim Analysis Of Global Phase 3 Colorectal Cancer Study 51
Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa 52
Jan 17, 2017: XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet Oncology 53
Other Significant Developments 54
Aug 10, 2018: XBiotech Highlights Quarterly Developments 54
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57
XBiotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XBiotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XBiotech Inc, Deals By Therapy Area, 2012 to YTD 2018 9
XBiotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XBiotech Enters into Agreement with Cedars-Sinai Medical Center 11
Xbiotech Enters into Research Agreement with Case Western Reserve University School of Medicine 12
Xbiotech Enters into Agreement with NCIC Clinical Trials 13
Xbiotech Enters into Research Agreement with South Texas Blood & Tissue Center 14
XBiotech Enters into Licensing Agreement with CT Atlantic 15
Megapharm Enters into Licensing Agreement with XBiotech for Xilonix 16
Xbiotech Enters Into Licensing Agreement With Lonza Sales 17
XBiotech Enters Into Licensing Agreement With Strox Biopharma 18
Xbiotech Raises USD31.8 Million in Public Offering of Shares 19
XBiotech Raises USD1 Million in Public Offering of Shares 20
XBiotech Raises USD1.8 Million in Public Offering of Shares 21
Xbiotech Raises USD76 Million in IPO 22
XBiotech Inc, Key Competitors 23
XBiotech Inc, Key Employees 24
XBiotech Inc, Subsidiaries 25
List of Figures
XBiotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XBiotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9